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Summary Background: State Medicaid programs provide insurance coverage to
over 40 million Americans. However, estimates of the annual cost of chronic
obstructive pulmonary disease (COPD) from the Medicaid perspective are lacking.
Methods: This retrospective cohort study used Medicaid administrative claims
data from California and Florida to estimate COPD expenditures using two
alternative methods: (1) excess costs (comparing a COPD cohort to a matchedee front matter & 2005
med.2005.10.001
ing author. Tel.: +1 781
ess: jmenzin@bhei.comcomparison cohort); and (2) attributable costs (COPD-related expenditures within a
COPD cohort, inclusive of respiratory medications). The COPD cohort in each state
included Medicaid recipients not dually eligible for Medicare who were 40+ years of
age with at least one medical claim for COPD during 2001. The comparison cohort
consisted of patients with medical claims during 2001 for conditions other than
chronic respiratory disease, matched by age, sex, and race to the COPD cohort.
Results: A total of 6738 Medicaid recipients in California and 18,017 in Florida were
included in the COPD cohort, with mean ages of 56 and 60 years, respectively.
Comorbidities, especially congestive heart failure and vascular disease, were more
common in the COPD cohort than among matched controls. The mean excess cost of
COPD per-patient was estimated to be approximately $6500 in California Medicaid and
$5200 in Florida Medicaid. Mean attributable costs of COPD were similar in the two
Medicaid programs (approximately $2200 and $2300 per patient, respectively).
Conclusions: COPD places a substantial financial burden on State Medicaid
programs. These findings may be of interest to clinicians and policy-makers involved
in preventing or managing this chronic disease.
& 2005 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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Chronic obstructive pulmonary disease (COPD) is an
important cause of morbidity and mortality in the
US, and a major source of healthcare costs.1 It has
been estimated that 10–16 million persons in the US
have been diagnosed with some form of COPD, and
that as many as 14–16 million more remain
undiagnosed.2–5 COPD currently ranks as the fourth
leading cause of death in the US after heart
disease, cancer, and cerebrovascular disease, with
about 120,000 annual deaths.4–7 The prevalence,
morbidity, and mortality of COPD have increased
over time, and are expected to increase with the
aging of the US population.8,9
COPD is a slowly progressive disease of the
airways characterized by airflow limitation and
gradual loss of lung function that is not fully
reversible.5,8 It is considered ‘‘a preventable and
treatable disease state’’.10 In the US, the term
COPD includes chronic bronchitis, chronic obstruc-
tive bronchitis, emphysema, and combinations of
these conditions.5 Symptoms of COPD include
wheezing, cough, sputum production, and dyspnea,
with the latter the most prominent and disabling
symptom and the most common reason for patients
to seek medical care.11 Diagnosis is usually made on
the basis of medical history, physical examination,
and results from pulmonary function testing.9
Treatment options for COPD are aimed largely at
symptom control; these include inhaled and oral
bronchodilators, anti-inflammatory drugs, and sup-
plemental oxygen.9 However, cessation of smoking
is the only intervention that has successfully proven
to reduce rate of decline in lung function.12–14
Surgical treatment, such as bullectomy, lung
volume reduction surgery, and lung transplanta-
tion, is not an option for most patients.9,15
The direct and indirect costs of COPD have been
estimated at $32.1 billion in 2003.5,9 Direct costs
(i.e., those related to hospital care, physician and
other professional services, home care, nursing
home care, and pharmacy) accounted for $18
billion, while indirect costs (lost earnings due to
illness and lost future earnings resulting from
death) comprised $14.1 billion.5,9 Most US COPD
cost analyses are limited to Medicare or private
insurers, or have used fairly outdated national
survey data.3,7,16–22
The Medicaid program, financed by the US
Federal Government and individual states, covers
more than 40 million poor or medically needy
persons, or about 14% of the population. Each state
organizes its own services under Medicaid and
finances up to 50% of the program costs. The
economic burden of COPD is an important issuefrom the Medicaid perspective given that smoking,
the most important risk factor for this disease, has
a 50–100% higher prevalence among Medicaid
recipients versus the general population.23–25 In
addition, adults eligible for Medicaid assistance
have poorer health status than other adults.26 The
objective of the present study was to use data from
two large state Medicaid programs to estimate the
direct costs of COPD.Methods
Data sources
California Medicaid
California Medicaid (‘‘Medi-Cal’’) is the largest
state Medicaid program in the US, with over 8
million recipients.27 Total program expenditures
exceeded $19.8 billion in 2001,27 of which $4.3
billion represented capitated payments to managed
care organizations. The major components of
expenditures for non-capitated care included hos-
pitalization and nursing homes ($6.1 billion),
prescription medications ($2.8 billion), personal
support ($2.8 billion), hospital outpatient and
clinics ($1.1 billion), and physician and laboratory
services ($1.1 billion).
The database used in this study consisted of
administrative claims and eligibility information for
a 20% random sample of Medi-Cal recipients. The
Medi-Cal eligibility file included recipient age, sex,
race, whether or not the recipient was eligible for
Medi-Cal services in each month, and dual (i.e.,
Medicaid and Medicare) coverage status. The
claims files included details on prescriptions filled
(National Drug Code, dispense date, quantity of
medication prescribed, and therapy days supplied),
outpatient services (date of service, type of
service, and one ICD-9-CM diagnosis code), and
institutional services (type of facility, admission
and discharge dates, primary and secondary ICD-9-
CM diagnosis code, and procedures performed).
A total of approximately 1.04 million California
Medicaid recipients were eligible for full benefits in
the 20% file as of the start of our study period,
419,000 of whom were eligible for fee-for-service
coverage (see Cohort Selection below).
Florida Medicaid
The Florida Medicaid program is the fourth largest
in the US with 2.5 million recipients.28 Total
program expenditures exceeded $8.4 billion in
2001,28 of which $0.9 billion represented capitated
payments to managed care organizations. The
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tated care included hospitalization and nursing
homes ($3.5 billion), prescription medications
($1.5 billion), personal support ($0.3 billion),
hospital outpatient and clinics ($0.6 billion), and
physician and laboratory services ($0.5 billion).
The database used for analysis consisted of
administrative claims and eligibility information
for Florida Medicaid recipients drawn from the
entire population of recipients. The Florida Medi-
caid database, which is similar in structure to the
Medi-Cal database, included eligibility information
and claims for institutional medical services, out-
patient medical services, and prescription drugs.
A total of approximately 1.96 million Florida
Medicaid recipients were eligible for benefits as of
the start of our study period, of whom 1.44 million
were eligible for fee-for-service coverage.Cohort selection
The initial study population included all Medicaid
recipients in the state of Florida and a 20% random
sample of Medicaid recipients in California. These
recipients were required to have fee-for-service
coverage (i.e., non-capitated prescription drug and
medical benefits) as of the beginning of the study
period (i.e., January 1, 2001 through December 31,
2001 for California, and July 1, 2000 through June 30,
2001 for Florida). Recipients who were eligible for
both Medicaid and Medicare (primarily those 65 years
of age and older) were excluded from the analysis
since complete claims details often are lacking for
this population. We also excluded Medicaid recipients
under 40 years of age, since COPD would be expected
to be uncommon in this age group.
From each database, Medicaid recipients with a
diagnosis of COPD (‘‘COPD cohort’’), and those with
no respiratory disease diagnoses (‘‘comparison
cohort’’), were selected from the initial popula-
tion, as follows:
COPD cohort: All recipients having one or more
medical claims with a primary or secondary
diagnosis of chronic bronchitis (ICD-9-CM diagnosis
codes 491.xx), emphysema (ICD-9-CM 492.xx), or
chronic airway obstruction not elsewhere classified
(ICD-9-CM 496.xx) during the study period were
included in the COPD cohort.
Comparison cohort: All recipients who had no
claims with a primary or secondary diagnosis for
respiratory disease (ICD-9-CM codes 491.xx through
496.xx) but had one or more claims for other
medical services with a valid ICD-9-CM diagnosis
during the study period were candidates for
inclusion in the comparison cohort. Patients fromthis pool were selected at random and matched, on
a one-to-one basis, with patients in the COPD
cohort by age (exact year), sex, and race/ethnicity.Study measures
Healthcare utilization and excess cost of COPD. We
evaluated the use of healthcare services and
medications among the COPD and comparison
cohorts in each Medicaid program. In addition,
the excess cost of COPD was estimated as the mean
of the per-patient differences in overall medical
and pharmacy expenditures between the COPD and
matched comparison cohorts. Resource utilization
and expenditures also were evaluated by category
of service (i.e., inpatient, outpatient, home
healthcare, physician, drugs).
Attributable cost of COPD. The attributable cost
of COPD was assessed by accumulating all Medicaid
payments for medical claims that had a listed
diagnosis (primary or secondary) of COPD and
adding the cost of respiratory medications. The
latter included beta-agonists, anticholinergics,
methylxanthines, glucocorticoids, and combina-
tions of these therapies.
Our assessment focused on direct medical costs
only. Indirect costs (e.g., from lost productivity due
to illness) were not included since this information
is not recorded in Medicaid databases.Data analyses
Descriptive analyses of patient characteristics were
performed for the COPD and comparison cohorts,
including demographics, comorbidities, and dura-
tion of Medicaid eligibility. To assess the prevalence
of comorbidities, medical claims from 2001 were
reviewed. A total of 17 binary variables were
created, each corresponding to a chronic disease
contained in the comorbidity scale developed by
Charlson and colleagues.29 The method of Deyo
et al.,30 which established ICD-9-CM codes for each
of these 17 conditions, was used to create the
binary comorbidity variables from the claims
database. Finally, these conditions were weighted
to create a single comorbidity score.29 The Charl-
son comorbidity classification scheme was em-
ployed because it has been validated in several
other studies using administrative claims data.29–32
Because of potential overlap with COPD, chronic
pulmonary disease was excluded from calculations
of the comorbidity score. In addition, we docu-
mented whether patients in the COPD cohort had
asthma (ICD-9-CM 493.xx) as a primary or secondary
diagnosis during the study period.
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excess and attributable—also were analyzed
descriptively. The contribution of comorbidity to
excess cost, calculated as the paired difference in
costs for the COPD cohort and matched controls,
was assessed through multivariate modeling based
on analysis-of-covariance (least-squares means),
which included the Charlson comorbidity score,
the presence of concomitant asthma (in the COPD
cohort), and controlled for length of follow-up. An
alternative model that included all of the available
comorbidities individually also was estimated, but
yielded similar findings and therefore is not
reported herein. For cost measures, standard errors
also were calculated.
All data analyses were conducted using the
Statistical Analysis System (SAS) software package.33Results
Patient characteristics
A total of 24,755 Medicaid recipients with COPD
(and an equal number of matched controls) met
cohort selection criteria: 6738 in California and
18,017 in Florida. These patients were identified as
follows. In the Medi-Cal program, using the 20%
data file, 16,752 recipients were found to have at
least one medical claim with a COPD diagnosis.
From this group, 8871 were excluded due to dual
Medicare–Medicaid eligibility, 79% of whom were 65
years of age or older. An additional 1143 patients
were excluded because they were under 40 years of
age. In Florida Medicaid, 42,495 recipients had a
COPD diagnosis. From this group, 17,758 were
excluded due to dual Medicare–Medicaid eligibility,
78% of whom were 65 years of age or older. Another
6720 were excluded because they were under 40
years of age.
The mean age of study patients was 56 years in
California and 60 years in Florida, with 53% and 58%
female, respectively. Twenty-eight percent and 21%
of patients in the COPD cohort had a concomitant
asthma diagnosis. Comorbidities, especially con-
gestive heart failure and vascular disease, were
more common in the COPD cohorts than among
matched controls. This pattern of comorbidities
was found in both the California and Florida
Medicaid programs (Table 1).
Healthcare utilization
The proportion of patients hospitalized was higher
in the COPD cohorts in both programs (Table 2). As aresult, COPD patients spent, on average, an
additional 3.2 and 4.2 days in the hospital in
California and Florida, respectively, during the
study year. The proportions of patients using
hospital outpatient services, home health-care
services or durable medical equipment, and physi-
cian services also were higher in the COPD cohorts
in both state Medicaid systems. The only exception
was for nursing facility admissions, which were
higher in the COPD cohort in California, but lower
in Florida. For the COPD cohort, 32% and 16%
underwent spirometry during 2001 in California and
Florida, respectively.
The use of all types of medications, both
respiratory and non-respiratory, was higher in the
COPD cohort (Table 3). Nearly three-quarters of
patients in the COPD cohort used antibiotics versus
50% in the comparison cohort. Approximately one-
half of patients in the COPD group used short-acting
beta-agonists, while about 20% used anticholiner-
gics, inhaled steroids, or systemic steroids, and 10%
used long acting bronchodilators or xanthines
(Table 4). These usage patterns were similar in
both state Medicaid programs.Medicaid expenditures
Excess costs of COPD. The mean (7 standard error)
excess costs of COPD per-patient in the California
and Florida Medicaid programs were estimated
at $64687 $319 and $52427$188, respectively
(Table 5). Approximately one-half of these costs
were associated with inpatient treatment. Addi-
tional expenditures associated with prescription
drugs and physician visits accounted for most of the
remaining differences in each state. Based on
multivariate analyses, asthma and other comorbid-
ity in the COPD cohort accounted for 47% and 43% of
the excess cost in California and Florida, respec-
tively. Median excess costs were estimated to be
$2952 in California and $3711 in Florida.
Attributable costs of COPD. The mean (7 standard
error) attributable costs of COPD per patient in the
California and Florida Medicaid programs were
similar ($21607$97 and $23377$35, respectively),
of which approximately one-half was associated
with hospitalization.
Relative costs of COPD. The mean per-patient
cost for a COPD patient was estimated to be
$12,952 in California, which is about five times
average per-capita spending ($2405) in the
state for the same year (2001).34 Corresponding
figures for the Florida Medicaid program are
$16,503 and $3528.34
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Table 1 Characteristics of COPD and matched comparison cohorts, by state Medicaid program, 2001.
Measure California Medicaid Florida Medicaid
COPD cohort
(n ¼ 6738)
Comparison cohort
(n ¼ 6738)
COPD cohort
(n ¼ 18; 017)
Comparison cohort
(n ¼ 18; 017)
Age
40–54 years 45.1% 45.1% 35.6% 35.6%
55–64 years 40.3% 40.3% 37.2% 37.2%
65+ years 14.6% 14.6% 27.2% 27.2%
Mean7SD 56.179.6 56.179.6 59.5711.8 59.5711.8
Percent male 47.1% 47.1% 42.2% 42.2%
Race
White 55.6% 55.6% 52.6% 52.6%
Black 21.2% 21.2% 13.9% 13.9%
Asian 19.1% 19.1% 0.2% 0.2%
Hispanic 4.1% 4.1% 6.8% 6.8%
Other 0.0% 0.0% 26.6% 26.6%
Charlson comorbidity index
(Mean7SD)
1.572.2 0.971.7 1.572.1 1.071.8
Selected Charlson comorbidities (%):
Myocardial infarction 4.6% 2.1% 5.3% 2.0%
Congestive heart failure 17.9% 5.5% 17.9% 4.9%
Peripheral vascular disease 8.0% 2.7% 7.7% 3.5%
Cerebrovascular disease 14.1% 6.8% 12.2% 6.7%
Rheumatologic disease 7.3% 3.6% 2.9% 2.3%
Peptic ulcer disease 7.1% 3.7% 3.7% 1.7%
Diabetes 31.2% 24.7% 25.7% 19.4%
Liver disease 4.1% 3.0% 3.6% 2.2%
Any malignancy 7.9% 5.5% 9.2% 6.4%
Metastatic solid tumor 2.3% 1.1% 2.7% 1.6%
Asthma (%) 28.1% 0.0% 20.6% 0.0%
Other selected comorbidities (%):
Depression 9.9% 6.7% 17.8% 11.2%
Hip fracture 1.9% 1.0% 1.9% 1.2%
Number of months of eligibility
(Mean7SD)
11.571.8 11.172.5 11.272.1 10.872.7
This calculation excludes chronic pulmonary disease.
J.P. Marton et al.1000Discussion
This retrospective study used data from two large
state Medicaid programs to estimate the annual
direct medical costs of COPD from the Medicaid
system perspective. Using two different estimation
methodologies, our findings suggest that the
costs of COPD, on a per-recipient basis, range from
approximately $2200 to $6500 in California, and
$2300 to $5200 in Florida. There have been
numerous published studies on the economic
burden of COPD, but we believe this is the first to
focus specifically on state Medicaid programs. Our
estimate of excess cost is comparable to those from
other claims-based studies that examined differentpayer perspectives. For example, Mapel and col-
leagues, using administrative claims data from a US
managed-care organization, estimated mean costs
of COPD at $6039 per patient (1997 US dollars),22
or $7023 adjusted to 2001 dollars. Grasso and
colleagues, using Medicare claims, estimated per-
patient COPD costs at $4971 (1992 US dollars),17
or $7133 in 2001 dollars. Two studies based on
survey data derived somewhat lower estimates.
Halpern and colleagues,35 using data derived from
the US sample of the international COPD survey,
Confronting COPD in North America and Europe,
estimated costs at $4120 (2000 US dollars). Miller et
al. derived an estimate of excess costs of $4932
(2000 US dollars) using data from the Medical
ARTICLE IN PRESS
Table 2 Healthcare utilization for COPD and matched comparison cohorts, by state Medicaid program and
component, 2001.
Measure California Medicaid Florida Medicaid
COPD cohort
(n ¼ 6738)
Comparison cohort
(n ¼ 6738)
COPD cohort
(n ¼ 18; 017)
Comparison cohort
(n ¼ 18; 017)
Inpatient
Acute hospital care
Percent hospitalized 32.3% 13.3% 46.6% 18.5%
Mean (7 SD) hospital days per
patient
4.9714.0 1.778.9 5.6710.8 1.475.2
Nursing facility admissions
Percent with NF admissions 7.4% 4.7% 9.3% 11.4%
Mean (7 SD) NF days per
patient
13.1761.8 11.6762.3 18.0771.6 31.1797.5
Outpatient
Percent with hospital
outpatient services
67.7% 56.5% 72.1% 62.5%
Percent with durable medical
equipment
38.1% 14.5% 47.1% 9.4%
Physician
Percent with physician visits 96.5% 82.0% 92.8% 87.9%
Table 3 Drug utilization for COPD and matched comparison cohorts, by state Medicaid program, 2001.
Measure California Medicaid Florida Medicaid
COPD cohort
(n ¼ 6738)
Comparison cohort
(n ¼ 6738)
COPD cohort
(n ¼ 18; 017)
Comparison cohort
(n ¼ 18; 017)
Respiratory-related
Percent with prescription 57.6% 11.7% 65.7% 17.1%
Mean (7SD) number of
prescriptions per patienty
1.471.7 0.270.5 1.771.7 0.370.7
Antibiotics
Percent with prescription 73.5% 46.9% 74.1% 52.1%
Mean (7SD) number of
prescriptions per patienty
1.571.4 0.871.0 1.771.6 1.071.2
Other
Percent with prescription 97.7% 88.8% 94.8% 90.2%
Mean (7SD) number of
prescriptions per patienty
13.479.2 8.277.2 13.478.4 9.277.0
Overall
Percent with prescription 98.4% 89.7% 95.3% 90.9%
Mean (7SD) number of
prescriptions per patienty
16.3710.2 9.277.8 16.779.7 10.477.9
Percent of patients with any prescription in category.
yNumber of prescriptions for unique drugs, excluding refills.
Assessing the costs of chronic obstructive pulmonary disease: The state medicaid perspective 1001Expenditure Panel Survey (MEPS), with an attribu-
table cost estimate of $2507; the latter figure
compares favorably with our estimate.36Our findings have several implications with
respect to the Medicaid population. First, the
excess cost of COPD for Medicaid recipients is
ARTICLE IN PRESS
Table 4 Respiratory drug utilization for COPD patients, by slate Medicaid program, 2001.
Measure California Medicaid Florida Medicaid
Short acting beta agonists
Percent with prescription 49.3% 55.2%
Mean (7SD) number of medications dispensed per usery 5.476.2 6.576.3
Long acting beta agonists
Percent with prescription 9.7% 10.7%
Mean (7SD) number of medications dispensed per usery 3.272.9 3.673.1
Anticholinergics
Percent with prescription 20.8% 21.9%
Mean (7SD) number of medications dispensed per usery 4.374.8 4.874.5
Methylxanthines
Percent with prescription 8.9% 15.4%
Mean (7SD) number of medications dispensed per usery 4.773.8 6.374.2
Inhaled glucocorticosteroids
Percent with prescription 19.1% 22.0%
Mean (7SD) number of medications dispensed per usery 3.172.9 3.873.3
Systemic glucocorticosteroids
Percent with prescription 18.6% 28.1%
Mean (7SD) number of medications dispensed per usery 2.772.8 3.373.4
Combination long acting beta agonists and glucocorticosteroids
Percent with prescription 1.7% 2.0%
Mean (7SD) number of medications dispensed per usery 1.771.0 1.370.6
Percent of patients with any prescription in category.
yNumber of medications dispensed, including refills.
J.P. Marton et al.1002notable since it appears to be comparable to that
estimated for Medicare17 and private insurance22
populations despite the fact that the average age
of patients in our study was at least 10 years
younger. Second, the high prevalence of smoking in
the Medicaid population relative to the general US
population23–25 means that counseling regarding
smoking cessation and financial coverage for smok-
ing cessation aids are worthy of consideration.
However, as of 2002, 15 Medicaid programs still did
not provide coverage for tobacco-dependence
treatment, which falls short of the 2010 national
health objective of providing such coverage in all
states.25 Moreover, Medicaid recipients and the
uninsured have been shown to be less likely to
receive smoking cessation counseling in their
physicians’ office when compared to persons with
private insurance coverage.37
A strength of this study is that we employed two
alternative costing approaches. The attributable
cost approach only counts medical services that list
a diagnosis of COPD. Since COPD patients have
multiple comorbidities, in some cases those condi-
tions may be coded rather than COPD, resulting in
an underestimation of costs. This may be especiallyproblematic for physician services, as only one
diagnosis is coded in many claims databases. The
excess cost method measures the overall difference
in expenditures, regardless of specific diagnoses,
between patients with COPD and a non-respiratory
disease comparison group matched on sociodemo-
graphic factors. Some of the estimated excess costs
may reflect other, related medical conditions. For
example, we found a higher prevalence of other
illnesses in the COPD cohort that are linked to
smoking, such as cardiovascular disease, stroke,
and cancer. These comorbidities were estimated to
account for 35–38% of the excess cost of COPD.
Asthma as a concomitant diagnosis was found to
contribute an additional 8–9% to excess costs.
Because both of the costing approaches have merit,
we elected to report both here.
There are several limitations to our study. First,
Medicaid claims for persons with dual Medicaid and
Medicare coverage were not complete. These
patients, representing more than 40% of the overall
number with COPD, were therefore excluded from
the analyses. Future studies that take a broader
government perspective (e.g., both Medicare and
Medicaid) would be of interest, especially given the
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J.P. Marton et al.1004recent passage of a new Medicare prescription drug
benefit. Second, the study used data from only two
state Medicaid programs. While California and
Florida comprise about 20% of the entire US
Medicaid population, additional state-specific stu-
dies in other regions of the US would be valuable.
Finally, health insurance claims data have known
limitations. For instance, the use of ICD-9-CM codes
(e.g., the specific diagnosis codes or the number of
times they occur during the one-year study period)
to assess prevalent cases of COPD has not, to our
knowledge, been validated against objective clin-
ical data, such as spirometry results.
In summary, results from this study suggest that
the costs of COPD from the Medicaid perspective
are substantial and consistent in the two states
evaluated. These findings may be of interest to
clinicians and policy-makers involved in preventing
or managing this chronic disease.Acknowledgments
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